ANIP vs SUPN

For growth investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger pick with 43. 8% revenue growth year-over-year, versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). ANI Pharmaceuticals, Inc. (ANIP) offers the better valuation at 24. 7x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate ANI Pharmaceuticals, Inc. (ANIP) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, ANI Pharmaceuticals, Inc.

is actually cheaper at 9. 0x.

Over the past 5 years, ANI Pharmaceuticals, Inc.

(ANIP) delivered a total return of +148. 8%, compared to +75. 6% for Supernus Pharmaceuticals, Inc. (SUPN). Over 10 years, the gap is even starker: SUPN returned +223. 7% versus ANIP's +80. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ANI Pharmaceuticals, Inc.

(ANIP) is the lower-risk stock at 0. 56β versus Supernus Pharmaceuticals, Inc. 's 0. 80β — meaning SUPN is approximately 42% more volatile than ANIP relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 60% for ANI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ANI Pharmaceuticals, Inc.

(ANIP) is pulling ahead at 43. 8% versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). On earnings-per-share growth, the picture is similar: ANI Pharmaceuticals, Inc. grew EPS 419. 2% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ANI Pharmaceuticals, Inc.

(ANIP) is the more profitable company, earning 8. 9% net margin versus -5. 4% for Supernus Pharmaceuticals, Inc. — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIP leads at 9. 2% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ANI Pharmaceuticals, Inc.

(ANIP) trades at 9. 0x forward P/E versus 20. 8x for Supernus Pharmaceuticals, Inc. — 11. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ANIP: 51. 5% to $124. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56)). Both have compounded well over 10 years (ANIP: +80. 2%, SUPN: +223. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ANIP is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.